Therapy-related Leukemia Cutis after Adjuvant Chemotherapy in a breast cancer patient

Lee, Haur Yueh; Ng, Heng Joo; Wong, P.; Pang, Shiu Ming

doi:10.2340/00015555-0911

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with the features of this case. 10 However, we still cannot determine whether the lymphoma and leukemia were associated with the chemotherapy because we did not obtain conclusive evidence. However, it is undeniable that this is a special event.…”

Section: Discussionmentioning

confidence: 93%

How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy

Zhang

et al. 2016

Cancer Biology & Therapy

View full text Add to dashboard Cite

ABSRTRACTThe latest studies suggest that prophylactic chemotherapy or adjuvant chemotherapy for early stage breast cancer may increase the leukemia risk in patients. For patients with a low risk for breast cancer recurrence, physicians who make the choice for adjuvant therapy should consider the risk of its long-term side effects. Is the occurrence of lymphatic system cancer and leukemia after breast cancer treatment associated with chemotherapy? Can these types of leukemia be classified as therapy-related leukaemias? We believe that there may be correlations between any diseases, butwe cannot rush to conclusions or dismiss a correlation because we understand little about the diseases themselves.In this paper, we present a case of secondary diffuse large B-cell lymphoma and leukemia in patients after breast cancer chemotherapy, it is undeniable that this is a special event. For two distinct tumouroccurrences at different times, we cannot give a clear explanation because of thechanges in the genes that might link them together and we hope to attract the attention of other clinicians.

show abstract

Section: Discussionmentioning

confidence: 93%

How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy

Zhang

et al. 2016

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…It is very unusual for leukaemia cutis to develop as a response to chemotherapy, which is used for the treatment of leukaemia 9. A review of the literature reveals only a few case reports documenting this phenomenon, with cyclophosphamide as the presumed culprit.…”

Section: Discussionmentioning

confidence: 99%

Leukaemia cutis after starting bendamustine: cause or coincidence?

Mawri¹,

Nabi

Jallad

et al. 2015

BMJ Case Reports

View full text Add to dashboard Cite

SUMMARYA 55-year-old man with a history of chronic lymphocytic leukaemia presented with diffuse skin lesions that began 1 week after starting a new chemotherapy regimen with bendamustine and rituximab. The lesions appeared as erythematous papules that were neither itchy nor tender, and did not blanch with pressure. Initially, they began on his scalp and flanks and, over the next few days, spread diffusely throughout his body, becoming darker in colour. Skin biopsy showed atypical clonal B-cell proliferation in a perivascular, periadnexal and dermal band-like distribution, which was further characterised by immunohistochemical evaluation. These findings were suggestive of leukaemia cutis and consistent with the patient's chronic lymphocytic leukaemia, which was previously confirmed by bone marrow biopsy. The bendamustine was stopped and the patient's chemotherapy regimen was switched to fludarabine, cyclophosphamide and rituximab. Shortly thereafter, the leukaemia cutis regressed significantly. BACKGROUND

show abstract